NuVasive reported GAAP net income of $19.201 million for the first three months of 2022, compared to a $7.51 million loss in the previous year. Revenue increased 8.4% to $265.973 million from $245.451 million a year earlier.

NuVasive's GAAP loss for 2021 was $64.086 million, up 72.5% from $37.153 million in the prior year. Revenue increased 8.4% to $1.139 billion from $1.051 billion a year earlier.

NuVasive's GAAP loss for 9M 2021 was $27.35 million, down 29.6% from $38.845 million in the prior year. Revenue increased 10.3% to $836.913 million from $758.775 million a year earlier.

NuVasive's GAAP loss for the six months of 2021 was $5.711 million, down 7.5 times from $44.717 million in the previous year. Revenue increased 22.1% to $566.077 million from $463.493 million a year earlier.